CGON (CG Oncology) Stock Based Compensation: $35.33 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CGON CG Oncology Inc CGON
30 GF Score
Price $72.34
GF Value $119.46
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is CG Oncology Stock Based Compensation?

CG Oncology CGON +0.49% 30 Stock Based Compensation is $35.33 Mil as of Jun. 2026. GuruFocus rates CGON with a GF Score™ of 30/100 and a GF Value™ of $119.46 (Possible Value Trap). The stock has 5 warning signs investors should review.

CG Oncology's Stock Based Compensation for the three months ended in Jun. 2026 was $14.33 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was $35.33 Mil.

CG Oncology Stock Based Compensation Related Terms

CG Oncology Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for CG Oncology's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CG Oncology Stock Based Compensation Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
1.11 0.68 1.53 11.40 26.68

CG Oncology Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.01 7.33 7.19 6.47 14.33
CGON
30GF Score
CG Oncology Inc CGON
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CG Oncology Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $35.33 Mil.

What does a Stock Based Compensation of $35.33 Mil mean?
CG Oncology (CGON) has a Stock Based Compensation of $35.33 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for CG Oncology and its competitors.
Is CG Oncology's Stock Based Compensation too high?
CG Oncology's current Stock Based Compensation is $35.33 Mil. Overall, CG Oncology has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CG Oncology's Stock Based Compensation compare to ERAS and TVTX?
CG Oncology's Stock Based Compensation of $35.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for CG Oncology and its competitors. CG Oncology's current Stock Based Compensation is $35.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CG Oncology stock overvalued right now?
Based on GuruFocus' analysis, CG Oncology (CGON) is currently considered Possible Value Trap. The stock's GF Value™ is $119.46, compared to a current price of $72.34 — trading 39.4% below its estimated fair value. The current Stock Based Compensation is $35.33 Mil. CG Oncology's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For CG Oncology (CGON), the current Stock Based Compensation is $35.33 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CG Oncology (CGON) Overvalued in 2026?

Based on GuruFocus' analysis, CG Oncology stock appears to be undervalued. The current stock price of $72.34 is trading 39.4% below its estimated GF Value™ of $119.46. GuruFocus considers CG Oncology to be Possible Value Trap.

Key valuation signals for CGON:

  • Stock Based Compensation: $35.33 Mil
  • GF Value™: $119.46 vs. price of $72.34 (39.4% below fair value)
  • GF Score™: 30/100 with 5 warning signs

No single metric tells the full story. See the CGON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CG Oncology Business Description

Address 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
30GF Score

Get the complete analysis for CGON

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$72.34
Price
$119.46
GF Value